Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 Feb;17(2):e93-e100.
doi: 10.1016/j.ijid.2012.08.005. Epub 2012 Oct 22.

High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis

Jesse T Jacob  1 , Carlos A DiazGranados
Affiliations
Meta-Analysis

High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis

Jesse T Jacob et al. Int J Infect Dis. 2013 Feb.

Abstract

Background: Patients with methicillin-resistant Staphylococcus aureus (MRSA) infections caused by isolates with a high but 'susceptible' minimum inhibitory concentration (MIC) to vancomycin may suffer poor outcomes. The aim of this study was to determine the association of high compared to low vancomycin MICs and clinical outcomes (treatment failure and mortality) in patients with MRSA infections.

Methods: PubMed, the Cochrane Library, and electronic abstracts from meetings were queried from January 2000 to July 2010. Two reviewers independently screened titles and abstracts of studies evaluating outcomes of patients with MRSA infections, using broth microdilution (BMD) or the Etest to determine MIC, for full-text review. Patients participating in included studies were classified into two mutually exclusive groups: high MIC or low MIC. High MIC was defined as MIC ≥1mg/l by BMD or ≥1.5mg/l by Etest. Study-defined failure and mortality were assessed in each group.

Results: Fourteen publications and six electronic abstracts met the inclusion criteria, with 2439 patients (1492 high MIC and 947 low MIC). There was no evidence of publication bias or heterogeneity. An increased risk of failure was observed in the high MIC group compared to the low MIC group (summary risk ratio (RR) 1.40, 95% confidence interval (CI) 1.15-1.71). The overall mortality risk was greater in the high MIC group than in the low MIC group (summary RR 1.42, 95% CI 1.08-1.87). Sensitivity analyses showed similar findings for failure (summary RR 1.37, 95% CI 1.09-1.73) and mortality (summary RR 1.46, 95% CI 1.06-2.01) for patients with bacteremia. The study quality was poor-to-moderate, and study-defined endpoints were variable.

Conclusions: A susceptible but high MIC to vancomycin is associated with increased mortality and treatment failure among patients with MRSA infections.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Results of the search strategy for the meta-analysis.
Figure 2
Figure 2
Funnel plot comparing the standard error (SE) of the logarithm of the risk ratio (RR) to the RR.
Figure 3
Figure 3
Forest plot comparing risk ratios for the outcomes of (A) failure, and (B) mortality, comparing patients in the high minimum inhibitory concentration (MIC) group to patients in the low MIC group stratified by method of testing for MIC (Etest vs. broth microdilution (BMD)).
Figure 4
Figure 4
Forest plot for the sensitivity analysis assessing only bloodstream infections, comparing risk ratios for the outcomes of (A) failure, and (B) mortality, comparing patients in the high minimum inhibitory concentration (MIC) group to patients in the low MIC group stratified by method of testing for MIC (Etest vs. broth microdilution (BMD)).
See this image and copyright information in PMC

References

    1. Moellering RC., Jr Vancomycin: a 50-year reassessment. Clin Infect Dis. 2006;42(Suppl 1):S3–4. - PubMed
    1. Ploy MC, Grelaud C, Martin C, de Lumley L, Denis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet. 1998;351:1212. - PubMed
    1. US Centers for Disease Control and Prevention . CDC reminds clinical laboratories and healthcare infection preventionists of their role in the search and containment of vancomycin-resistant Staphylococcus aureus (VRSA) CDC; Atlanta, GA: [accessed April 24, 2011]. 2011. Available at: http://www.cdc.gov/HAI/settings/lab/vrsa_lab_search_containment.html.
    1. Clinical and Laboratory Standards Institute . Performance standards for antimicrobial susceptibility testing. CLSI approved standard M100-S16. CLSI; Wayne, PA: 2006.
    1. Tenover FC, Moellering RC., Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis. 2007;44:1208–15. - PubMed

Publication types

MeSH terms